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Background: HPV vaccination decision-making is a complex process that is influenced by multiple psychosocial
determinants. Given the change in policy recommendation to include males in routine HPV vaccination, our goals
were to assess the HPV vaccination uptake in Canada, to understand where Canadian parents were situated in the
HPV vaccine decision-making process for their son, how they changed over time and which psychosocial
determinants were relevant for this process.
Methods: We used an online survey methodology and collected data from a nationally representative sample of
Canadian parents of boys aged 9–16 at baseline (T1, February 2014) and at 9 months’ follow-up (T2). Our analyses
were guided by the Precaution Adoption Process Model (PAPM), a theoretical health behavior model that classifies
parents in one of six stages: unaware, unengaged, undecided, decided not to vaccinate, decided to vaccinate and
those who had already vaccinated their sons. Rigorous methods were used to filter out careless responders:
response variance, bogus items, psychometric antonyms and psychometric synonyms.
Results: At T1 and T2, we received 3,784 and 1,608 respectively completed questionnaires; after data cleaning 3,117
(T1) and 1,427 (T2) were retained. Less than 3% of boys were vaccinated at both time points. At both T1 and T2,
most parents (over 70%) belonged to the earlier vaccination adoption stages: 57% were unaware (T1) and 15.3%
(T2); 20.9% were unengaged (T1) and 32.4% (T2); and 9.1% were undecided (T1) and 25.2% (T2). At follow-up,
37.7% of participants did not move from their initial PAPM decision-making stage. Most parents (55%) preferred to
receive information from their healthcare provider (HCP) but only 6% (T1) and 12% (T2) had actually spoken with a
HCP about the HPV vaccine for their son.
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Conclusions: HPV vaccination uptake in Canadian boys was very low in the absence of a publicly funded HPV
vaccination programs for boys. Optimal HPV information preferences were identified and can be used in
interventions to increase HPV knowledge and increase HPV vaccine uptake. Intentions to vaccinate or planning to
speak to one’s HCP did not translate into action for most parents over the 9-month follow up; this finding is critical
to consider to inform implementation strategies. Methodological challenges are described and suggestions for
future research are offered.
Keywords: Human papillomavirus, Cancer prevention, Vaccination, Determinants of health, Health decision-making,
Health behavior, Precaution Adoption Process Model, Parents, Boys, Knowledge, Attitudes, BeliefsBackground
The prevention of human papillomavirus (HPV)-associ-
ated diseases is an increasingly prominent public health
issue. HPV is the most common sexually transmitted in-
fection (STI) and accounts for 4.8% of the worldwide
cancer burden [1, 2]. HPV has been traditionally viewed
as an infection that impacts females [3, 4], even though
it poses a significant disease burden for males. Current
data suggests that 100% of cervical, 88% of anal, 70% of
vaginal, 50% of penile, 43% of vulvar and 13–56% of oro-
pharyngeal cancers are attributable to HPV [3]. Like fe-
males, males are at risk also for contracting HPV-
associated genital warts (GW), which can negatively
impact quality of life [3].
The quadrivalent vaccine, Gardasil® (Merck) protects
against four strains of HPV: two oncogenic strains (HPV
16, 18), and two that cause GW (HPV 6 and 11) [5].
Epidemiological studies from Australia, Canada, UK and
the US demonstrate population level reductions in the
rates of HPV, GW, and cervical cancer lesions after intro-
duction of HPV vaccine programs for girls [6–11]. With
strong empirical evidence for both vaccine safety and effi-
cacy [5], the HPV vaccine is an important innovation in
cancer prevention [6, 12].
In 2007, in Canada, the HPV vaccine (Gardasil®) was
recommended for females and subsequently rolled out
for females only in school-based immunization programs
[13]. As the research evidence grew, demonstrating the
burden of HPV-associated diseases in males, many
argued for vaccination of males [14]. Inclusion of males
in HPV immunization programs grew further because:
1) HPV vaccine uptake rates among females are failing
to reach sufficient levels (of at least 70%) to confer herd
immunity to heterosexual males, 2) female-only pro-
grams do not offer protection to men having sex with
men (MSM); and 3) a gender specific vaccine raises is-
sues of equity [14–22].
Presently, all Canadian provinces and territories offer
free, school-based HPV vaccination programs for females.
Canada’s National Advisory Committee on Immunization
(NACI, 2012 and 2015) recommends HPV vaccine for
females and males aged 9–26 [2]; this recommendation isconsistent with that of other nations (e.g., US [23]
Australia [24] and some of the European Union, e.g.
Germany (Saxony), Italy (Emilia-Romagna, Sicily) [25, 26].
In February 2013, Australia was the first country to extend
national vaccination programs for boys. In Canada, the
HPV vaccination program for males has unfolded as
follows. In September 2013, Prince Edward Island (PEI)
began including boys in grade 6 in their school-based
HPV vaccination programs. Alberta and Nova Scotia
subsequently followed in September 2014 for grade 5 boys
and in autumn 2015 for grade 7 boys respectively. In
September 2015, British Columbia (BC) began offering
the HPV vaccine without cost for “at risk” males e.g.,
MSM and ‘street-involved’ youth [27]. Similarly, as of
January 2016, Quebec offers the HPV vaccine without
cost to MSM aged 9–26. Beginning in September 2016,
Ontario, Quebec and Manitoba will include boys in their
school-based programs (grades 7, 4 and 6, respectively)
[14, 28]. In contrast with the female programs, only
Alberta and Ontario offer catch-up programs for older
boys. When this research study was developed (2012), no
HPV vaccinations programs for males existed in Canada
or elsewhere in the world.
The examination of the attitudinal, behavioral, cognitive,
social, cultural and logistical determinants (hereafter re-
ferred to as psychosocial) that influence the HPV-vaccine
decision-making is a growing area of research [29–36].
Because HPV was traditionally considered an (an infec-
tion) that affects females only, the vast majority of behav-
ioral research has been conducted among samples of
females or parents of daughters [31, 37]. To the best of
our knowledge, there are very few studies examining HPV
vaccine decision-making that were conducted exclusively
among parents of boys [35, 37]. In the Canadian context,
only two studies outside the present one examine the
psychosocial decision-making process among Canadian
parents of sons; both studies were conducted before the
HPV vaccine was recommended for males and therefore
the outcome variable reflects intentions to vaccinate rather
than actual vaccination uptake [38, 39].
Further, experts in HPV vaccine behavioral research rec-
ommend using theoretical health behavior frameworks to
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influence an individual’s vaccine decision-making process
[30, 40, 41]. Many studies that examine the correlates of
HPV vaccine decision-making utilize the Health Belief
Model (HBM) [31, 42]. The linear HBM attempts to
understand better HPV vaccine decision-making by focus-
ing on attitudes and beliefs about the costs and benefits of
HPV vaccination that are relevant only to people who have
been engaged (or are presumed to be engaged) sufficiently
by the HPV vaccination to have formed such beliefs [43].
As such, most existing studies examine the psycho-
social determinants that predict vaccination intentions
and/or uptake are for a group of individuals who are
assumed to be already aware and engaged in HPV
vaccination [31, 37, 42]. Since this group does not
include everyone—and with respect to HPV vaccin-
ation likely captures few parents because HPV vaccin-
ation for males is relatively new and many parents
may not yet have formed their beliefs—there are
likely other stages in adopting HPV vaccination. The
Precaution Adoption Process Model (PAPM) is a cat-
egorical stage theory, which aims to identify all the
stages involved when people commence health-
protective behaviors. The PAPM is therefore appropri-
ate to apply to parental decision-making about HPV
vaccination to determine the psychosocial determi-
nates that lead parents to move from one stage to the
next, and ultimately to vaccinate their child [44].
The PAPM consists of six1 distinct stages of health
decision-making: 1) unaware of the health behavior); 2)
unengaged in the decision; 3) undecided; 4) decided not
to act; 5) decided to act (intending); and 6) acting (vacci-
nated). As opposed to linear models, the PAPM staged
model acknowledges the fact that transition between
stages can be explained by different psychosocial deter-
minants, i.e. there are differences between determinants
which influence the transition from stage 1 to 2 com-
pared to the determinants which influence the transition
from stage 5 to 6.
Using a longitudinal design and online survey meth-
odology guided by the PAPM, we surveyed a national
sample of Canadian parents of boys to understand
where Canadian parents currently stand in the HPV
vaccine decision-making process for their son and
which psychosocial determinants influence their HPV
vaccination decision-making process. Importantly, the
present study was conducted just before several
Canadian provinces began to include males in their
school-based public vaccination program. This created
a unique opportunity to provide baseline data about
HPV vaccine uptake in the absence of publicly funded
programs, and to evaluate the impact of recent
recommendations of male HPV vaccination.
The study objectives were:1. To provide an estimate of HPV vaccine uptake
among males in Canada;
2. To classify where Canadian parents’ stand in the
HPV vaccine decision-making process for their son
(s) using the PAPM, at baseline (Time 1, T1) and at
follow-up 9 months later (Time 2, T2);
3. To describe how Canadian parents’ changed in their
HPV vaccine decision-making process from T1 to
follow-up (T2); and
4. To describe and analyze which psychosocial
determinants influence parents’ HPV vaccine
decision-making process i.e., PAPM stage
This research article will present a comprehensive de-
scription of the study methodology, sample characteristics
as well as the results for objectives 1–3. Descriptive result
for objective four, specifically for the following psycho-
social determinants: HPV and HPV vaccine Knowledge,
HPV vaccination information sources, health behaviors
(i.e., primary decision-maker, routine check-ups with a
healthcare provider (HCP), and childhood immunization
practices) and implementation intentions will be pre-
sented. A more comprehensive statistical analysis of the
psychosocial determinants of PAPM stages over time i.e.,
objective 4, is under way.
Methods
Recruitment
The population of interest was Canadian parents and/or
guardians (hereafter referred to as parents) of 9–16 year-
old boys. We selected this population because it covers
the current NACI HPV vaccine recommendation for
males aged 9–26, and because after the age of 16, virtu-
ally all Canadian minors may make a vaccination choice
without parental consent [45, 46]. Data collection was
facilitated by Leger2 a polling and market research firm
that maintains a national panel of 400,000 Canadians
across the 10 provinces. The first wave of data collection
occurred between February 7 and 25, 2014. E-mail invi-
tations to complete a ~20-min online questionnaire were
sent to 29,867 panelists who met the study’s inclusion
criteria (i.e., those who had a 9–16-year-old son living in
their household) according to data Leger maintains on
their panelists. These invitations were followed by
16,004 reminder emails (between 1 and 3 emails per par-
ticipant). The second wave of data collection occurred
between October 27 and November 19, 2014. E-mail
invitations were sent to 3,135 participants who were
eligible from T1 to participate at T2. These invitations
were followed by 8,341 reminder emails were (between 1
and 5 emails). At the time of data collection, HPV vac-
cination for males in Canada was just commencing; PEI
had initiated a school-based HPV vaccination program
for boys five months before (~Sept 2013) our T1 data
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(~Sept 2014) our T2 data collection. See Fig. 1 for a
detailed schematic of study participants following study
recruitment and data cleaning.
Procedure
Prior to beginning the questionnaire, participants were
asked first if they prefer to answer the questionnaire in
English or French and were provided the questionnaire in
the language of preference. Participants were also asked to
agree to answer the questions truthfully and thoughtfully
or were excluded from completing the study. Participants
were also asked at the beginning of the questionnaire to
provide a name, nickname, initials or abbreviations for
their son who is between the ages of 9 and 16 and who
has had the nearest birthday. Using intelligent program-
ming, the provided sons’ initials, name or nickname (e.g.,
Dan) was then replaced for my son in most items, making
the questionnaire individualized for each participant. InFig. 1 Flow diagram of study participantsthis way, participants were asked about their beliefs and
attitudes relative to one specific son. Participants were
informed that their son’s name will not be used in any
other way by the researchers. Participants were required
to complete every item, obviating the problem of missing
data. For 16 sensitive questions, “I prefer not to answer”
was a response option provided. In order to further ensure
recollection of answering the questionnaire at T1,
participants were asked at T2 “Do you remember
completing the survey related to the HPV vaccine about
my son?” Participants who indicated no recollection were
not invited to participate at T2. Respondents were




A 2010 systematic review of measures used in HPV vaccine
acceptability research called for standardized theoretical
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mendation included: 1) utilizing theory to guide construct
definitions [47, 48]; 2) employing cognitive testing [49]; 3)
reviewing measures by panels of experts [39, 47, 48, 50]; 4)
measuring intentions and actual behavior through clear
definitions (e.g., asking about compliance to recommended
number of doses) [51]; and, 5) development of con-
structs to take into account language and literacy
levels [48, 49, 52]. Our questionnaire development ad-
hered to all five recommendations, including a ‘think
aloud’ pilot testing of the questionnaire with 20 parents of
9–16-year-old boys. The questionnaire was developed,
reviewed and approved by a bilingual panel of seven expe-
rienced HPV researchers.
The English questionnaire was translated into French by
a specialized translation firm and reviewed for accuracy by
an independent bilingual group of professionals (n = 5)
working in the healthcare field. The questionnaires were
virtually identical at T1 and T2 except for minor differ-
ences (e.g., demographic items were removed at T2; items
related to conspiracy beliefs were added at T2). The
complete questionnaire3 contained 165 items at T1 and
191 items at T2, and is available by contacting the corre-
sponding author. A summary of the questionnaire con-
structs, sample items and response options are provided
in Additional file 1.
Socio-demographics (12 items)
The first 12 items were standard socio-demographic
variables (e.g., province, education, religion) selected
from Statistics Canada 2011 Census questionnaire. We
compared our sample to data the authors requested
from Statistics Canada’s National Household Survey
(2011) of participants who met our inclusion criteria i.e.,
parents of 9–16-year-old sons (n = 2,336,115) residing in
the 10 Canadian provinces in order to assure the
generalizability of our results to the entire Canadian
population. First, chi-square tests were performed to
examine if there were any significant differences in
socio-demographics between our T1 and T2 samples.
Next, chi-square tests were performed to examine if
there were any significant differences in socio-
demographics between T1 and Statistics Canada’s
sample (see Table 1). Because statistical significant
differences (p < 0.05) in proportions do not indicate the
size of the difference, we further calculated Cohen’s h
[53] (see Table 1). Consistent with Cohen’s recommen-
dations, we interpreted h ≤ 0.2 as small, h = 0.5 as
medium and h ≥ 0.8 as a large difference [53].
PAPM stage (1 item)
The primary outcome variable in our study was parents’
self-reported HPV vaccine decision-making stage, i.e.,
PAPM stage. Parents were asked: “Before today, whichof the following best describes your thoughts about the
HPV vaccine concerning my son?” Six response options
were provided which allowed us to classify parents
according to six distinct categorical stages of HPV vac-
cine decision-making (see Additional file 1). Of note,
after assessing socio-demographics and HPV and HPV
vaccine knowledge and just prior to assessing the outcome
variable i.e., PAPM stage, participants were provided with
a brief informative statement about HPV and the HPV
vaccine in order to ensure that they had some basic
awareness as to what HPV and the HPV vaccine was4.
Psychosocial determinants
HPV and HPV vaccine knowledge items (36 items)
There is mixed evidence for the relationship between
HPV-general and HPV-vaccine knowledge and parents’
HPV vaccination intentions/uptake for their child [40, 54,
55]. In order to assess what parents know about HPV and
the HPV vaccine, we utilized Waller and colleagues exist-
ing psychometrically-tested, validated 16-item HPV and 7-
item HPV vaccine scales [56]. We added 9 general HPV
knowledge items and 4 HPV-vaccination specific items
that were missing from the scale (e.g., items assessing
about whether parents know about the link between HPV
and other HPV-associated cancers beyond cervical
cancer), (see Additional File 1). Items answered correctly
were assigned 1 point while incorrect and “don’t know”
were assigned 0 points to generate a total HPV-general
and HPV vaccine knowledge scores.
Attitudes and beliefs (61 Items)
HPV-specific vaccination attitudes and general vaccine be-
liefs has been associated with parental vaccination inten-
tions and uptake [37, 57]. The authors generated a list of
200 potential attitudinal items found after reviewing the
psychosocial HPV vaccine literature and selected items
based on constructs derived from different theoretical
models of health behavior, including the HBM and the
Theory of Reasoned Action) [58]. For each attitude and
belief item, a 7-point Likert response format with 1 =
Strongly Disagree, 4 = Neutral and 7 = Strongly Agree
was used (see Additional file 1).
Information sources (6 items), health behaviors (6 items),
implementation intentions (3 items) and other items
Participants were asked about the sources where they
actually heard about the HPV vaccine and the sources
they would prefer receiving information about the HPV
vaccine. They were also asked if, and what type of
recommendation (for, against, neutral, or neither) they
received from a HCP for their son concerning the HPV
vaccine. Self-reported health behaviors were also assessed
e.g., whether their son has attended a routine medical
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who the primary health decision-maker was for their son
(e.g., mother, father or joint).
Lastly, parents were also asked about behaviors they
intended to complete at T1 (e.g., contact an HCP, search
the internet), and at T2, using the computer-adaptive
testing, we re-assessed if the specified behaviors they
indicated at T1 were indeed carried out by T2.
Other additional items include: if the participant have any
daughters and/or any vaccinated daughters (2 items);
parent's health behaviours (3 items) communication about
sex/HPV vaccination (7 items); degree of parental/son
involvement in HPV vaccine decision-making (3 items),
willingness to vaccinate at different price points (4 items);
vaccine conspiracy beliefs (9 items) [59]; right wing
authoritarianism (7 items); beliefs about other parents who
do not vaccinate their child (2 items) and the Conspiracy
Mentality Questionnaire (5 items) [60] are found in the
additional file.Data cleaning
Addressing careless/unmotivated responders
Once data collection was completed, we sought to ensure the
highest level of data quality and integrity of our conclusions.
We used four data cleaning methods to identify participants
who might not have used appropriate care while completing
the questionnaire i.e., careless or unmotivated responders [61].
The four methods employed were: variance, bogus items,
psychometric antonyms and psychometric synonyms [61]. For
the variance criterion, we examined 64 items (some reverse
coded) dispersed across 7 separate web pages in our online
questionnaire. There were 13, 9, 7, 11, 8, 10 and 6 items across
the 7 different web pages. We flagged participants who had 0
variance across the items on more than 4 of the 7 pages.
For the validity criterion, we used three bogus items
from Weinberger and colleagues [62]: “I have never met
anyone younger than I am”; “Everyone makes mistakes
at least once in a while”, and “I am answering these
questions truthfully” with response options ranging from
1= “strongly disagree” to 7 = “strongly agree”, where 4 =
“neutral”. We reverse coded the first item and created a total
validity score for the three items. We removed participants
who scored 12 or below, then, re-introduced any participant
who answered “neutral” to all three items. The rationale for
this cut-off was that we sought to identify participants who
scored below “neutral” (somewhat disagree, disagree and
strongly disagree) given that the correct answer to these items
was to “agree” with them (note that the opposite is true for
the one reverse coded item). We chose to re-introduce any
participant who answered “neutral” to all three items as these
items are available for subjective interpretation and those who
were systematically answering “neutral” to all items would be
removed by the variance method.Another method used was psychometric synonyms
and antonyms [61, 63], which are consistency indices
that help to eliminate bias by examining differences in
items that are highly similar or opposing in content. We
examined any questionnaire item that had a 7-point
Likert response option. Post hoc, we standardized all
relevant items into z scores and correlated all items. We
identified the 30 most positively and 30 most negatively
correlated items. We recoded these items to create pairs
of synonyms and then calculated the correlation between
synonyms and antonyms for each participant, which
established a synonym index and an antonym index for
each participant. We then flagged all values less than -2
standard deviations (SD) on the synonyms index and
greater than +2 SD on the antonyms index as these
correlations could be seen as extreme outliers.
These four methods identified that 15% of our sample
at T1 (n = 575) and 5% of our sample (n = 202) at T2
belonged to a latent class that can be considered careless
or unmotivated in their responses, a percentage nearly
identical to findings by other research groups [61, 64].
Data collected from these participants were removed
from our final sample (see Fig. 1).
Self-report of son’s vaccination status
Following T1 data collection, we inspected the data from
our primary outcome variable, PAPM stage. The authors
observed that some participants’ responses were im-
plausible, nonsensical or inaccurate. We speculated that
perhaps parents may have confused the HPV vaccine
with other childhood vaccinations, and therefore some
participants likely did not match the profile of a partici-
pant who had truly vaccinated his or her son against
HPV. For example, some participants indicated that
their son had been vaccinated in school, even though
they lived in provinces where indeed no school-based
programs for boys yet existed. This challenge of self-re-
port (i.e., subjective) vaccination as opposed to objective
(e.g., vaccination booklet with official stamps or elec-
tronic vaccination registries) has been reported in the
literature [65, 66].
During data cleaning at T1, the authors therefore
established a first method of examining a set of 10
criteria to increase the likelihood that parents who had
indicated that they had vaccinated their son were not
false positives. Furthermore, in order to improve upon
the accuracy of parents’ self-reported vaccination status,
at T2, we prompted those who selected PAPM stage 6
(i.e., vaccination) with a brief informative statement
about the Canadian HPV vaccine policy (e.g., we in-
formed participants that except for PEI, parents have to
pay/purchase the HPV vaccine) and then asked the
PAPM stage item a second time to ensure that their
PAPM stage was as accurate as possible.
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impossible PAPM stage transitions. From both a theoret-
ical and practical perspective, it is impossible for some-
one to report being in stages 2–6 at T1, and then to
report being in stage 1 at T2. For such a report to be
true, the participant would need to have become un-
aware, after having previously been aware that the HPV
vaccine could be administered to males. The second
issue was the impossibility of someone moving from
reporting that their son had been vaccinated (Stage 6) at
T1, to then reporting any other stage at T2 (i.e. implying
that their son is no longer vaccinated). In total, using
the aforementioned three methods, 92 participants were
removed from the final sample due to likely inaccurate
or implausible vaccination stage (see Fig. 1).
Statistical analysis was conducted using SPSS v23
and R v3.2.2.Table 2 PAPM stages at Time 1 and Time 2
PAPM Stage Time 1 Time 2
n % n %
I was unaware that the HPV vaccine could be
given to males (Stage 1)
1778 57.0 218 15.3
I was aware that the HPV vaccine can be given
to males, but I have not thought about getting
the HPV vaccine for my son (unengaged, Stage 2)
652 20.9 462 32.4
I have thought about getting the HPV vaccine
for my son, but I am undecided about getting
the HPV vaccine for him (Stage 3)
284 9.1 360 25.2
I have decided I do NOT want my son to get
the HPV vaccine (Stage 4, decided not to)
212 6.8 208 14.6
I have decided I DO want my son to get the
HPV vaccine (Stage5, decided to)
157 5.0 140 9.8
My son has already received the HPV vaccine
(Stage 6, vaccinated)
34 1.1 39 2.7Results
The mean time to complete the questionnaire was 21 min
at T1 and 24 min at T2.
Participants and socio-demographics
The final cohort consisted of 3,117 participants at T1 and
1,427 at T2, representing a 45% attrition rate (see Fig. 1
for recruitment overview). The response rate, calculated
based on completion by participants who initiated the
questionnaire (n = 5733 at T1 and n = 1999 at T2), was
66.0% at T1 and 80.4% at T2. The sample’s socio-
demographic characteristics are presented in Table 1.
When comparing the T1 and T2 samples, the samples
were found to be similar as there were no significant
differences on all socio-demographic variables except
for two provinces and language (see Table 1). We had
significantly more respondents from Quebec and fewer
respondents from Saskatchewan at T2 compared to T1
but the difference was small (h ≤ 0.2). We also had
fewer English respondents and more French respon-
dents at T2 compared to T1, and the difference was
small as well (h ≤ 0.2).
A comparison of the T1 and Statistics Canada sam-
ples revealed that there were statistically significant
differences for the proportions of responses between
the two samples for all provinces (except Alberta,
Manitoba and Saskatchewan), language (except bilin-
guals), gender, education, marital status, employment
status, income (except those earning between $40 000
and $59 999 and those earning between $60 000 and
$79 999), nationality, ethnicity and religion (see Table 1).
An examination of the effect size indicates that the
effect size was small for 14 differences and medium for
18 differences (see Table 1). In no case, was the effect
size large (see Table 1).PAPM stages
The number and percentage of parents across the six
PAPM stages is presented in Table 2. The HPV vaccination
uptake of Canadian males 9-16 years old was very low, with
only 34 and 39 parents reporting that their sons were vacci-
nated at T1 and T2, which represents an HPV vaccine up-
take rate of 1.1% at T1 and 2.7% at T2. Of the few parents
who indicated that they had vaccinated their son, 47% re-
ceived one dose at T1 and 56% at T2 (p > 0.05). Two or
three doses were reportedly received by 53% of sons at T1
and 44% at T2 (χ2 = 0.32, CI: -0.34; 0.16, p > 0.05).
While there was a free school-based program in place
for boys in Grade 6 in PEI, our results still show that 19
parents from PEI were unaware, unengaged or un-
decided. At T2, there was a program in place for boys in
Grade 5 in Alberta, and our results indicate that 85
parents were unaware, unengaged or undecided from
these two provinces. Moreover, at T1, only 1 parent
from the 34 (2.9%) who reported their son was vacci-
nated were from provinces offering free HPV vaccination
for boys (PEI) and at T2, 11 from the 39 (28.2%) were
parents of vaccinated sons who were from provinces that
were vaccinating boys against HPV as part of the provin-
cial immunization schedule (PEI and Alberta).
HPV and HPV vaccine knowledge
We validated and extended Waller et al.’s existing
knowledge scales and create a 25-item HPV general
knowledge scale and the 11-item HPV vaccine know-
ledge scale, which were found to be psychometrically
robust [67].
The mean scores for HPV knowledge were 11.67 (from
25 possible points) at T1 and 14.02 at T2 (t = 12.11, CI:
1.97; 2.73, p < 0.01). The mean scores for HPV
vaccination knowledge were 5.22 (from 11 possible points)
at T1 and 6.3 at T2 (t = 12.27, CI: 0.9; 1.24, p < 0.01).
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know/don’t know) and the relationship between know-
ledge and PAPM stages are presented elsewhere [67].
Attitudes and beliefs
We developed and validated a comprehensive,
psychometrically-sound HPV vaccination attitudes
and belief scale (HABS), which contains 46 items
and 9 factors: benefits, threat, influence, harms, risk,
affordability, communication, accessibility and general
attitudes (see Additional file 1). The psychometric proper-
ties of the scale are described in another paper [68].
Information sources
Most parents (94% at T1 and 88% at T2) never spoke
with a doctor /HCP about the HPV vaccine for their son
(χ2 = 40.4, CI: 0.04; 0.08 p < 0.01, h = 0.2).
Of the few parents (6% at T1 and 11.4% at T2) who did
speak to their doctors/HCP, 59% of them were recom-
mended to get the HPV vaccine for their son at T1 and
69% at T2 (χ2 = 3.33, CI: -0.21; 0.006, p = 0.07). At T1,
55.8% of those parents who vaccinated their son had
spoken with a HCP about the HPV vaccine. More than
half the sample (54%) at both T1 and T2 prefer to receive
their information from an HCP, which was by far the
most preferred source of information, followed by
public health brochures, pamphlets, flyers or posters
which was reported by 18% of parents at T1 and T2.
Parents reported that the sources from which they
actually received information about the HPV vaccine
(e.g., TV or radio) did not correspond with their most
preferred information source (e.g., from their HCP,
see Fig. 2).Fig. 2 Percentage of participant’s actual source of receiving HPV vaccine in
Time 1 and Time 2Health behaviors
At both time points, parents indicated that their son’s
healthcare decisions are typically a joint decision made
by both parents (60.4% at T1 and 62% at T2, χ2 = 0.5,
p > 0.05), followed by mothers alone (40.2% at T1 and
39% at T2, χ2 = 1.05, p > 0.05) and fathers alone (5% at T1
and 4.6% at T2, χ2 = 0.28 p > 0.05).
More than half of parents (61% at T1 and 59% at T2)
mentioned that their son underwent a routine checkup
with a healthcare provider in the previous year (χ2 = 2.07,
CI: -0.008; 0.054, p > 0.05). Most parents (93% at both T1
and T2) stated that their sons have received all childhood
vaccines. Interestingly, at T1 and T2 respectively, 25.5%
and 21.2% of parents who decided not to vaccinate their
son against HPV stated their son did not receive all recom-
mended childhood vaccines; the proportions were signifi-
cantly higher than parents belonging to any of the other 5
PAPM stages at both time-points (p < 0.05).
Implementation intentions
In most cases, parents did not implement their planned/
intended actions to facilitate HPV vaccination between T1
and T2. Parents increased the search for information about
HPV vaccine in written sources (i.e., brochures, books,
magazines) at T2 (21%) compared to T1 (15%) (see Fig. 3).
Some parents did not name a planned intention, but when
they stated nothing, they indeed remained in status quo.
Stage transitions from T1 to T2 (n = 1427)
We had 539 (37.7%) participants who remained in the
same stages of vaccination adoption (i.e., PAPM stage)
from T1 to T2; this includes 3 participants who indi-
cated at T1 that their sons were vaccinated. A higherformation compared to their preferred information sources at both
Fig. 3 Percentage of participant’s self-reported planned actions at Time 1 compared to actions reported as completed at Time 2 (Implementation
Intentions)
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advanced PAPM stages that are closer to action i.e.,
vaccination; 53 participants (3.7%) regressed (to earlier
stages than they initially were in, away from action); only
36 parents (2.5%) advanced to having their sons
vaccinated at T2. Of the 1238 participants who initially
identified as being unaware, unengaged or undecided
at T1 and who completed the T2 questionnaire, 27
progressed to vaccinated at T2. Of the 80 participants
who had decided to act at T1 and who completed the T2
questionnaire, only 9 participants (11%) progressed to
being vaccinated at T2. Not a single participant in stage 4
in T1 (i.e. decided not to act, n = 106) moved towards
decided to act or vaccination at T2. 130 participants
(9.1%) moved from unaware, unengaged, undecided or
decided to act at T1 to decided not to act at T2 (see Fig. 4).
Discussion
To our knowledge, this is the first HPV vaccination
specific survey in a pan-Canadian representative sample
of parents of boys after the first HPV vaccine (Gardasil®)
was licensed in Canada for males in September 2010
[14]. Other vaccination surveys such as the Childhood
National Immunization Coverage Survey (CNICS) con-
ducted by Statistics Canada have not been gender and
HPV specific [69], such that the data collected are less
representative of the Canadian population of parents ofboys and do include items about HPV vaccination for
males. At the time of data collection, only one of the ten
provinces at T1 (PEI), and two of the provinces at T2
(PEI and Alberta) had implemented school-based HPV
vaccination program for males, and no territories offered
school-based HPV vaccination for boys. As such, only a
small number of parents from PEI and Alberta and (i.e.,
only those with sons in grade 6 and 5 respectively) were
eligible for free school-based HPV vaccination programs.
In the absence of programs, the HPV vaccine uptake,
was exceptionally low at both T1 (1.1%, n = 34 from
3117) and T2 (2.7%, n = 39 from 1427).
Similarly, the lack of programs for boys, and in turn
the cost of vaccinations as well the lack of information
(e.g., not even knowing boys can get the HPV vaccine;
lack of understanding about the benefits/risks; no rec-
ommendation from a HCP) likely explains why at both
time-points most parents (87% at T1 and 73% at T2)
were in the first three stages of adoption (unaware, un-
engaged or undecided). Furthermore, post-hoc, we ex-
amined the few sons (n = 34 and T1 and n = 39 at T2)
who were vaccinated, and the majority was not even
from provinces that offered free-school based HPV
vaccination programs. Having two provinces that had
introduced male HPV vaccination programs did not ap-
pear to skew our ‘snapshot’ of parental HPV vaccine
decision. We were also able to establish a reliable
Fig. 4 Number of participant’s initial PAPM stage reported at T1 is shown on the y-axis. Number of participant’s who remained in the same PAPM
stage or their movement to a different PAPM stage at T2 shown on the x-axis (n =1427)
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(as of September 2016), there are six Canadian provinces
with HPV vaccination programs for males. The six Can-
adian provinces join only a handful of other countries/
regions e.g., Australia, Austria, Israel, Barbados, Lichten-
stein, New Zealand that have implemented or are set to
implement publicly funded HPV vaccination programs
for boys [25, 29, 30]. Our work offers valuable baseline
information to all stakeholders involved in implementing
and evaluating HPV vaccination programs.
At T2, almost half the sample moved forward along the
PAPM vaccine decision-making trajectory, with most
moving towards unengaged or undecided. Over a third of
the sample remained in the same stage as at baseline.
These results are not surprising, considering our study
was an observation design and not an intervention study.
Moreover, the movement towards the later stages of adop-
tion was minimal, i.e., very few parents moved towards
deciding to act and acting/vaccination. In the absence of
programs or targeted interventions that match parents’
informational needs, most parents remained fixed in their
current and/or earlier stages of adoption. The forward
movement along the PAPM vaccine decision-making
trajectory could likely be explained by parents acquiring
information through written sources (e.g., media) or
simply by virtue of completing the questionnaire at T1.
Furthermore, voluntary initiation of parents e.g. to
acquire information via the internet or to speak to
their HCP was not found at T2. Of those parentswho had decided to vaccinate their son at T1 i.e., had
intentions and who completed the T2 questionnaire,
very few parents followed through in vaccinating their
sons even when they were in the later stages of
decision-making. This finding supports a growing
body of research showing that there are important
gaps between intending to act and carrying out inten-
tions [70]. Therefore, some individuals likely require
help developing specific implementation plans to re-
duce the barriers.
Of interest, the most immobile group were those
who had decided not to vaccinate, with no parent in
this stage (of 106) moving toward intentions or
vaccination at T2. Our results complement previous
research suggesting that a proportion of these parents
may likely be hesitant towards all vaccines and not
uniquely against the HPV vaccine, and perhaps more
akin to what are known as “anti-vaxxers” [71, 72].
For the entire sample, HPV knowledge and HPV
vaccine knowledge remained poor at both time-
points. The relationship between parent’s knowledge
and vaccine acceptance/intentions is mixed and
equivocal [73–77]. Low knowledge in the present
group of parents could be explained by the relatively
new recommendation of the HPV vaccine for boys
and indicate the need to inform parents about the
link between HPV and penile, anal and oral cancers
as well as GW. Importantly, there were discrepancies
between preferred and actual HPV information
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ing more information on HPV vaccination, their
needs are not being met. Providing relevant, accurate
information about the recommendation and benefits
of the HPV vaccine for boys, ideally delivered by a
doctor or HCP, could improve HPV vaccine uptake.
Our results also indicated that the vast majority of
Canadian parents have not received a recommendation
from their HCP about the HPV vaccine for their sons
despite their HCP being the primary source they prefer
and want to receive information from. Moreover, while
the sample size is small (n =36), 80% of parents who ad-
vanced towards actual vaccination from T1 to T2 re-
ceived a recommendation from their HCP. An HCP
recommendation has almost consistently been shown to
be associated with increased parental HPV vaccine accept-
ability [73, 76, 78–80] and the absence of an HCP recom-
mendation has been associated with negative attitudes
and refusal of HPV vaccination [74–76, 80]. Facilitating
knowledge translation through HCPs should be a major
goal for future interventions to increase HPV knowledge
and in turn, improve HPV vaccination uptake [14]. Other
potential avenues where parents could acquire HPV infor-
mation is from public health brochures, pamphlets and
posters provided by government health organizations and
endorsed by different medical organizations (e.g. Canadian
Medical Association) which may be seen as an HCP en-
dorsement. Since other vaccines (e.g., Tdap, Hepatitis B
and meningococcal) are given to Canadian children at a
similar age/grade as the HPV vaccine, an opportunity ex-
ists to pair the vaccines together in administration and
educate parents about HPV vaccination.
The present study’s strengths are related to the study’s
longitudinal design, data collection tool (questionnaire),
data collection method (online survey to acquire a pan-
Canadian sample) and data cleaning techniques. The on-
line survey approach allowed us to: 1) use computer-
adaptive testing, 2) avoid missing data, and 3) collect
data in a time efficient way. Furthermore, by developing
a strong data-cleaning algorithm, we increased the reli-
ability of our final data. Moreover, the authors engaged
in extensive psychometric testing [67, 68] to ensure the
validity of the psychosocial constructs which has been
recommended in this area of research [33]. Additionally,
our study utilized a longitudinal design, which will allow
us to analyze how the psychosocial determinants influ-
ence HPV vaccine decision making over time. To the
best of our knowledge, there is only one existing lon-
gitudinal study of parents of boys which was con-
ducted outside of Canada [81]. Moreover, our results
confirmed that intentions do not translate into vac-
cination over time (only 7/80 of the decided to when
on to vaccinate their sons), which is often unknown
in most intention studies. Lastly, the use of thePAPM allowed us to capture HPV vaccine decision-
making in a more nuanced way, and not presume
that all parents are aware or engaged in this particu-
lar health behavior. Therefore, our results demon-
strate that in studying HPV decision-making, the
PAPM is likely a fitting theoretical model in contrast
to the HBM or IBM, which ignore the earlier stages
of vaccine decision-making.
Our study is limited in several ways. Compared to data
collected from Statistics Canada household survey sam-
ple of parents with 9-16-year-old, there were differences
in the structure of our sample. The effect size was
mostly small to medium with no effect size exceeding
0.6. In our opinion, the small to medium differences
allow us to generalize our results to the Canadian con-
text. Our suggestion for future studies would be to im-
pose quotas based on the repartition of respondents
consistently with national representative available data in
order to further reduce sample differences. Additionally,
our sample consisted of more mothers (65%) than
fathers (35%). Importantly, our response rate of males is
higher than in other studies reporting HPV vaccine
related attitudes where the average proportion of
mothers was 82.3% [37]. Therefore, in our opinion the
proportion of males and females in our sample closely
reflects the gender specific HPV vaccination decision-
making process in Canada. Participants were also lost to
follow-up, but importantly our T2 sample was comparable
and nearly identical to the original T1 sample on all socio-
demographic variables albeit province and language,
where the effect was small. Moreover, we were unable to
sample the three Northern territories constituting of
mostly Indigenous peoples (e.g., North American Indian,
Inuit), as these residents were not represented in Leger’s
panel. Future research should evaluate the psychosocial
determinants of HPV vaccine decision-making in this
population. Additionally, the present findings did not
analyze the confounding role of having daughters who are
eligible for HPV vaccination in the household. Future
analyses are underway which will examine whether having
a vaccinated daughter is a predictor of PAPM stage. A
final limitation was the recall bias of some participants’
self-reported vaccination status. The issue of inaccurate
self-report of vaccination as opposed to actual (e.g. vaccin-
ation booklet, physician’s record) has been reported in the
vaccine literature [65]. In the absence of an HPV
immunization school-based program, most males re-
ceive the HPV vaccine privately and the option to
register this information with national databases is
voluntary. As the HPV vaccination rate was extremely
low (1-3%) in our study, and the HPV vaccine was
not included in provincial immunization programs,
we have reason to believe that the lack of objective
proof of vaccination had only a small influence on
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ents’ self-reported vaccinated status may be unreliable
and should try to use objective records to precisely
measure HPV vaccine uptake.
Conclusions
Our results illustrate the exceptionally low uptake of the
HPV vaccine in Canadian boys in the absence of a funded
immunization program. Parents are critical to a successful
HPV vaccination program in children. Directing our
attention to males as much as females is important
because males play a role in transmission and are
vulnerable to HPV-associated diseases. This data can help
direct efforts towards helping Canadians become aware
that males are recommended to get the HPV vaccine and
be engaged in the decision to vaccinate their sons.
Moreover, intentions to vaccinate one’s son or
planning to speak to one’s HCP did not translate into
action for most parents over the 9-month follow-up.
These results have implications for implementation of
strategies (e.g., HCPs offering the HPV vaccine to the
parent of a son directly and immediately during a
routine visit, fostering resources within schools to
increase HPV vaccine uptake). Lastly, the use of
staged-based health behavior model, i.e., the PAPM,
allowed for more precision as to where parents stood
along the HPV vaccine decision-making trajectory.
Forthcoming analyses to better understand the psy-
chosocial determinants that influence each specific
stage will allow us to target the unique gaps and
barriers of each PAPM stage.
Endnotes
1The PAPM original model consist of seven stages of
health decision-making. The seventh stage is a mainten-
ance stage and does not apply to HPV vaccination. For
simplicity, only the six stages are described.
2Leger has the largest representative panel in Canada
and the largest Franco-Canadian panel. Since members
are recruited randomly over the phone, the Leger Panel
is highly representative and offers exceptional quality
respondents. Leger sampling process is based on data
from Statistics Canada (e.g., province, age, gender,
language and region).
3As the questionnaire was computer adapted, few
items were asked of only some groups. For example,
only those participants who indicated they vaccinated
their son, were further asked about how many doses
he received.
4The informative statement read as follows: Please
read carefully the following information about HPV.
The Human Papillomavirus (HPV) is the most com-
mon sexually transmitted infection. HPV can causegenital warts. HPV can also cause cancers of the
cervix, penis, anus, vagina, vulva and oral cancers.
There are HPV vaccines available that are sometimes
referred to as the cervical cancer vaccine, Gardasil®, or
Cervarix®. The HPV vaccine is given in 2 or 3 doses and
costs approximately $150–$200 per dose. Health Canada
has approved and recommended an HPV vaccine for both
males aged 9–26 years and females aged 9–45 years.
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